Santhera's vamorolone NDA receives priority review in China

Santhera has reported that the China NMPA granted priority review for a new drug application (NDA) for vamorolone for Duchenne muscular dystrophy.

Related Keywords

China ,United Kingdom ,Chinese , ,Sperogenix Therapeutics ,Drug Evaluation ,